| Statement |
1.Name of the securities:KRX (214370.KQ) Caregen Co.,Ltd.
2.Trading date:2025/11/25~2026/01/23
3.Date of the board of directors’ resolution:2026/01/08
4.Other approval date:NA
5.Amount, unit price, and total monetary amount of the
transaction:
(1)Amount：46,329 shares
(2)unit price：KRW81,268.66(equivalent to TWD 1,757.12)
(3)total monetary amount：KRW3,765,096thousand
(equivalent to TWD 81,406 thousand)
6.Gain (or loss) through disposal (not applicable in
case of acquisition of securities):
Gain on disposal: Equivalent to NT$53,864 thousand
(transferred from other equity to retained earnings;
please refer to other explanatory notes for details)
7.Relationship with the underlying company of the trade:NA
8.Current cumulative amount held, monetary value, and
shareholding percentage of cumulative holdings of the
securities being traded (including the current trade),
and status of any restriction of rights (e.g., pledges):
Cumulative amount held:
(1)Cumulative number of shares held: 172,500 shares
(2)Cumulative amount held: NT$52,407 thousand
(3)Shareholding ratio: 0.32%
(4)Pledge status: None
9.Current ratio of securities investment (including the
current trade) to the total assets and equity attributable
to owners of parent as shown in the most recent financial
statement and working capital as shown in the most recent
financial statement as of the present, as listed in the
Regulations Governing the Acquisition and Disposal of
Assets by Public Companies: Ratio to total assets:
(1)Proportion of total assets: 35.78%
(2)Proportion of equity attributable to owners of
the parent: 42.47%
(3)Amount of working capital in the most recent
financial statements: NT$693,774 thousand
10.Concrete purpose of the acquisition or disposal:
Ensure investment benefits
11.Whether the directors expressed any objection to
the current transaction:None
12.Whether the counterparty of the current transaction
is a related party:NO
13.Trading counterparty and its relationship to the
Company:None
14.Date of ratification by supervisors or approval by
the audit committee:2026/01/08
15.Date on which material information regarding the same event
has been previously released:2026/01/08
16.Any other matters that need to be specified:
The company's sale of the transaction target is a
financial asset designated as measured at fair value
through other comprehensive income (FVOCI).
|
